1. Academic Validation
  2. Selective and specific inhibition of the plasmodium falciparum lysyl-tRNA synthetase by the fungal secondary metabolite cladosporin

Selective and specific inhibition of the plasmodium falciparum lysyl-tRNA synthetase by the fungal secondary metabolite cladosporin

  • Cell Host Microbe. 2012 Jun 14;11(6):654-63. doi: 10.1016/j.chom.2012.04.015.
Dominic Hoepfner 1 Case W McNamara Chek Shik Lim Christian Studer Ralph Riedl Thomas Aust Susan L McCormack David M Plouffe Stephan Meister Sven Schuierer Uwe Plikat Nicole Hartmann Frank Staedtler Simona Cotesta Esther K Schmitt Frank Petersen Frantisek Supek Richard J Glynne John A Tallarico Jeffrey A Porter Mark C Fishman Christophe Bodenreider Thierry T Diagana N Rao Movva Elizabeth A Winzeler
Affiliations

Affiliation

  • 1 Novartis Institutes for BioMedical Research, Novartis Pharma AG, Forum 1 Novartis Campus, Basel, Switzerland. dominic.hoepfner@novartis.com
Abstract

With renewed calls for malaria eradication, next-generation antimalarials need be active against drug-resistant parasites and efficacious against both liver- and blood-stage infections. We screened a natural product library to identify inhibitors of Plasmodium falciparum blood- and liver-stage proliferation. Cladosporin, a Fungal secondary metabolite whose target and mechanism of action are not known for any species, was identified as having potent, nanomolar, antiparasitic activity against both blood and liver stages. Using postgenomic methods, including a yeast deletion strains collection, we show that cladosporin specifically inhibits protein synthesis by directly targeting P. falciparum cytosolic lysyl-tRNA synthetase. Further, cladosporin is >100-fold more potent against Parasite lysyl-tRNA synthetase relative to the human enzyme, which is conferred by the identity of two Amino acids within the enzyme active site. Our data indicate that lysyl-tRNA synthetase is an attractive, druggable, antimalarial target that can be selectively inhibited.

Figures
Products